ID

31989

Descrizione

A Pharmacokinetic (PK) and Pharmacodynamic (PD) Study of Golimumab in Patients With Rheumatoid Arthritis (RA); ODM derived from: https://clinicaltrials.gov/show/NCT01362153

collegamento

https://clinicaltrials.gov/show/NCT01362153

Keywords

versioni (1)
  1. 10/10/18 10/10/18 -
Titolare del copyright

See clinicaltrials.gov

Caricato su

10 ottobre 2018

DOI

Per favore, per richiedere un accesso.

Licenza

Creative Commons BY 4.0
Commenti del modello :

Puoi commentare il modello dati qui. Tramite i fumetti nei gruppi di articoli e articoli è possibile aggiungere commenti a quelli in modo specifico.

Torna ai commenti del modello
Commenti del gruppo di articoli per :

Commenti dell'articolo per :

Per scaricare i modelli di dati devi essere registrato. Per favore accesso o registrati GRATIS.

Eligibility Rheumatoid Arthritis NCT01362153

Inglese

Eligibility Rheumatoid Arthritis NCT01362153

1 moduli  
Inclusion Criteria
Descrizione

Inclusion Criteria

Alias
UMLS CUI
C1512693
have a diagnosis of ra for at least 3 months prior to screening
Descrizione

Rheumatoid Arthritis Disease length

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0003873
UMLS CUI [1,2]
C0872146
have no history of latent or active tuberculosis (tb) and test negative for tb
Descrizione

Latent Tuberculosis Absent | Tuberculosis Absent | Tuberculosis test negative

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C1609538
UMLS CUI [1,2]
C0332197
UMLS CUI [2,1]
C0041296
UMLS CUI [2,2]
C0332197
UMLS CUI [3]
C2242735
Exclusion Criteria
Descrizione

Exclusion Criteria

Alias
UMLS CUI
C0680251
have inflammatory diseases other than ra
Descrizione

Inflammatory disorder | Exception Rheumatoid Arthritis

Tipo di dati

boolean

Alias
UMLS CUI [1]
C1290884
UMLS CUI [2,1]
C1705847
UMLS CUI [2,2]
C0003873
have been treated with disease-modifying anti-rheumatic drugs (dmards)/systemic immunosuppressives other than methotrexate (mtx), sulfasalazine, or hydroxychloroquine during the 4 weeks prior to the first administration of study agent
Descrizione

Antirheumatic Drugs, Disease-Modifying | Immunosuppressive Agents Systemic | Exception Methotrexate | Exception Sulfasalazine | Exception Hydroxychloroquine

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0242708
UMLS CUI [2,1]
C0021081
UMLS CUI [2,2]
C0205373
UMLS CUI [3,1]
C1705847
UMLS CUI [3,2]
C0025677
UMLS CUI [4,1]
C1705847
UMLS CUI [4,2]
C0036078
UMLS CUI [5,1]
C1705847
UMLS CUI [5,2]
C0020336
have received intramuscular (im), iv, or intra-articular corticosteroids within 4 weeks of study agent administration
Descrizione

Adrenal Cortex Hormones Intramuscular | Adrenal Cortex Hormones Intravenous | Intraarticular injection of corticosteroids

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0001617
UMLS CUI [1,2]
C1556154
UMLS CUI [2,1]
C0001617
UMLS CUI [2,2]
C1522726
UMLS CUI [3]
C2064783
have a known hypersensitivity to human ig proteins
Descrizione

Human immunoglobulin allergy

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0571543
have received infliximab, golimumab, adalimumab or abatacept within 3 months, or etanercept or anakinra within 1 month prior to the first administration of study agent
Descrizione

infliximab | golimumab | adalimumab | abatacept | Etanercept | anakinra

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0666743
UMLS CUI [2]
C2353893
UMLS CUI [3]
C1122087
UMLS CUI [4]
C1619966
UMLS CUI [5]
C0717758
UMLS CUI [6]
C0245109
have received alefacept, efalizumab, natalizumab, rituximab, or any b-cell-depleting agent
Descrizione

alefacept | efalizumab | natalizumab | rituximab | B-cell depletion therapy

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0962603
UMLS CUI [2]
C1174995
UMLS CUI [3]
C1172734
UMLS CUI [4]
C0393022
UMLS CUI [5]
C1171324
have been treated with any other biologics or investigational drugs, within 5 half-lives of that drug prior to the first administration of study agent
Descrizione

Biological agents | Investigational New Drugs

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0005515
UMLS CUI [2]
C0013230
have a history of latent or active granulomatous infection, including tuberculosis (tb), histoplasmosis, or coccidioidomycosis, prior to screening
Descrizione

Granulomatous infection Latent | Granulomatous infection | Tuberculosis | Histoplasmosis | Coccidioidomycosis

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C1610637
UMLS CUI [1,2]
C0205275
UMLS CUI [2]
C1610637
UMLS CUI [3]
C0041296
UMLS CUI [4]
C0019655
UMLS CUI [5]
C0009186
have had a bacille calmette-guerin (bcg) vaccination within 12 months of screening
Descrizione

Bacillus Calmette-Guerin vaccination

Tipo di dati

boolean

Alias
UMLS CUI [1]
C4305105
have had a serious infection (eg, hepatitis, pneumonia, pyelonephritis, or sepsis)
Descrizione

Communicable Disease Serious | Hepatitis | Pneumonia | Pyelonephritis | Sepsis

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0009450
UMLS CUI [1,2]
C0205404
UMLS CUI [2]
C0019158
UMLS CUI [3]
C0032285
UMLS CUI [4]
C0034186
UMLS CUI [5]
C0243026
Ritorna all'inizio della pagina

Similar models

Eligibility Rheumatoid Arthritis NCT01362153

1 moduli
Name
genere
Description | Question | Decode (Coded Value)
Tipo di dati
Alias
Item Group
C1512693 (UMLS CUI)
Rheumatoid Arthritis Disease length
Item
have a diagnosis of ra for at least 3 months prior to screening
boolean
C0003873 (UMLS CUI [1,1])
C0872146 (UMLS CUI [1,2])
Latent Tuberculosis Absent | Tuberculosis Absent | Tuberculosis test negative
Item
have no history of latent or active tuberculosis (tb) and test negative for tb
boolean
C1609538 (UMLS CUI [1,1])
C0332197 (UMLS CUI [1,2])
C0041296 (UMLS CUI [2,1])
C0332197 (UMLS CUI [2,2])
C2242735 (UMLS CUI [3])
Item Group
C0680251 (UMLS CUI)
Inflammatory disorder | Exception Rheumatoid Arthritis
Item
have inflammatory diseases other than ra
boolean
C1290884 (UMLS CUI [1])
C1705847 (UMLS CUI [2,1])
C0003873 (UMLS CUI [2,2])
Antirheumatic Drugs, Disease-Modifying | Immunosuppressive Agents Systemic | Exception Methotrexate | Exception Sulfasalazine | Exception Hydroxychloroquine
Item
have been treated with disease-modifying anti-rheumatic drugs (dmards)/systemic immunosuppressives other than methotrexate (mtx), sulfasalazine, or hydroxychloroquine during the 4 weeks prior to the first administration of study agent
boolean
C0242708 (UMLS CUI [1])
C0021081 (UMLS CUI [2,1])
C0205373 (UMLS CUI [2,2])
C1705847 (UMLS CUI [3,1])
C0025677 (UMLS CUI [3,2])
C1705847 (UMLS CUI [4,1])
C0036078 (UMLS CUI [4,2])
C1705847 (UMLS CUI [5,1])
C0020336 (UMLS CUI [5,2])
Adrenal Cortex Hormones Intramuscular | Adrenal Cortex Hormones Intravenous | Intraarticular injection of corticosteroids
Item
have received intramuscular (im), iv, or intra-articular corticosteroids within 4 weeks of study agent administration
boolean
C0001617 (UMLS CUI [1,1])
C1556154 (UMLS CUI [1,2])
C0001617 (UMLS CUI [2,1])
C1522726 (UMLS CUI [2,2])
C2064783 (UMLS CUI [3])
Human immunoglobulin allergy
Item
have a known hypersensitivity to human ig proteins
boolean
C0571543 (UMLS CUI [1])
infliximab | golimumab | adalimumab | abatacept | Etanercept | anakinra
Item
have received infliximab, golimumab, adalimumab or abatacept within 3 months, or etanercept or anakinra within 1 month prior to the first administration of study agent
boolean
C0666743 (UMLS CUI [1])
C2353893 (UMLS CUI [2])
C1122087 (UMLS CUI [3])
C1619966 (UMLS CUI [4])
C0717758 (UMLS CUI [5])
C0245109 (UMLS CUI [6])
alefacept | efalizumab | natalizumab | rituximab | B-cell depletion therapy
Item
have received alefacept, efalizumab, natalizumab, rituximab, or any b-cell-depleting agent
boolean
C0962603 (UMLS CUI [1])
C1174995 (UMLS CUI [2])
C1172734 (UMLS CUI [3])
C0393022 (UMLS CUI [4])
C1171324 (UMLS CUI [5])
Biological agents | Investigational New Drugs
Item
have been treated with any other biologics or investigational drugs, within 5 half-lives of that drug prior to the first administration of study agent
boolean
C0005515 (UMLS CUI [1])
C0013230 (UMLS CUI [2])
Granulomatous infection Latent | Granulomatous infection | Tuberculosis | Histoplasmosis | Coccidioidomycosis
Item
have a history of latent or active granulomatous infection, including tuberculosis (tb), histoplasmosis, or coccidioidomycosis, prior to screening
boolean
C1610637 (UMLS CUI [1,1])
C0205275 (UMLS CUI [1,2])
C1610637 (UMLS CUI [2])
C0041296 (UMLS CUI [3])
C0019655 (UMLS CUI [4])
C0009186 (UMLS CUI [5])
Bacillus Calmette-Guerin vaccination
Item
have had a bacille calmette-guerin (bcg) vaccination within 12 months of screening
boolean
C4305105 (UMLS CUI [1])
Communicable Disease Serious | Hepatitis | Pneumonia | Pyelonephritis | Sepsis
Item
have had a serious infection (eg, hepatitis, pneumonia, pyelonephritis, or sepsis)
boolean
C0009450 (UMLS CUI [1,1])
C0205404 (UMLS CUI [1,2])
C0019158 (UMLS CUI [2])
C0032285 (UMLS CUI [3])
C0034186 (UMLS CUI [4])
C0243026 (UMLS CUI [5])
Ritorna all'inizio della pagina 

Contatto

Si prega di utilizzare questo modulo per feedback, domande e suggerimenti per miglioramenti.

I campi contrassegnati da * sono obbligatori.

Aiuto

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial